Endotoxin removal is one of the most persistent bottlenecks in bringing therapeutic bacteriophages to market. Produced by the outer membrane of Gram-negative bacteria, endotoxins (lipopolysaccharides, or LPS) can trigger severe immune reactions in patients if not reduced to ultra-low levels. For a Contract Development and Manufacturing Organization (CDMO), especially one producing phage therapies at GMP standards, the stakes are high: failure to meet endotoxin specifications can halt a clinical program or delay regulatory approval.

In therapeutic phage manufacturing, endotoxin challenges are magnified because most medically relevant phages—such as those targeting Pseudomonas aeruginosa, E. coli, and Klebsiella pneumoniae—are propagated in Gram-negative hosts. Every amplification step generates not only high titers of phage, but also large amounts of endotoxin-rich bacterial debris. For an Endotoxin CDMO specializing in phage products, this means designing processes that consistently meet regulatory thresholds (<5 EU/kg patient dose) without compromising phage potency, yield, or stability.

Why Endotoxin Removal Is So Critical in Phage Manufacturing

From a regulatory standpoint, endotoxin levels in injectable biologics are tightly controlled due to the risk of pyrogenic reactions—fever, hypotension, septic shock—in patients. Phage therapies are no exception. In fact, because phages are biological entities administered in relatively high doses, the allowable endotoxin load per treatment is often lower on a per-volume basis compared to some protein therapeutics.

For CDMOs, the challenge is compounded by the biology:

• High endotoxin load per batch due to Gram-negative hosts.
• Endotoxin’s strong association with cell debris and vesicles, making it difficult to separate from phage particles using simple filtration.
• Regulatory variability—some regions classify phages as biologics, others as ATMPs, each with its own endotoxin testing requirements.

An Endotoxin CDMO must therefore integrate removal strategies early in process design, not treat them as a final polishing step

Endotoxin Testing and Regulatory Requirements

Endotoxin measurement in therapeutic phage manufacturing relies primarily on the Limulus Amebocyte Lysate (LAL) assay, with kinetic chromogenic or turbidimetric methods providing quantitative readouts. Some facilities also use recombinant Factor C (rFC) assays for endotoxin detection to avoid animal-derived reagents.

Key regulatory expectations include:

• Defined endotoxin limits per dose and per mL, based on patient weight and administration route.
• Validated testing methods specific to the product matrix—phage buffers can sometimes interfere with LAL chemistry.
• In-process monitoring to track endotoxin clearance at multiple purification stages, not just in final product testing.

For an Endotoxin CDMO, maintaining compliance means building a quality system that not only measures endotoxin but documents control over every step that affects it.

Strategies for Endotoxin Removal in Phage Manufacturing

1. Clarification and Initial Debris Removal

The first opportunity to reduce endotoxin comes immediately after phage amplification:

• Centrifugation removes large cell debris but leaves soluble LPS and outer membrane vesicles (OMVs).
• Depth Filtration provides finer clarification while maintaining phage viability.

2. Tangential Flow Filtration (TFF)

TFF is a workhorse in phage purification, enabling buffer exchange and concentration. Using the right membrane cut-off (commonly 100–300 kDa) can wash away a significant portion of free endotoxin while retaining phage particles. However, endotoxin bound to OMVs or phage tails may require additional steps.

3. Chromatographic Endotoxin Removal

• Anion Exchange Chromatography (AEX): Exploits the negative charge of endotoxin to bind it while allowing phages to pass through or elute separately.
• Size Exclusion Chromatography (SEC): Separates phages from smaller endotoxin aggregates but is less effective for OMV-bound LPS.

4. Detergent-Based Methods

Mild non-ionic detergents can disrupt OMVs, releasing bound endotoxin for removal. This requires careful optimization to prevent phage inactivation.

5. Enzymatic and Adsorptive Approaches

Emerging methods include using endotoxin-binding resins or enzymes that degrade LPS, often as polishing steps after bulk removal.

For an Endotoxin CDMO, the key is integrating multiple complementary methods into a purification train that consistently achieves target specifications.

Balancing Purity, Yield, and Potency

One of the central tensions in phage manufacturing is that every step designed to remove endotoxin also risks losing phage particles. Over-aggressive filtration, extended buffer exchanges, or harsh chemical treatments can reduce infectious titers or alter phage morphology.

An experienced Endotoxin CDMO manages this balance by:

• Performing small-scale spiking and clearance studies to map the relationship between process conditions, endotoxin removal efficiency, and phage recovery.
• Using orthogonal removal steps to achieve additive clearance without over-stressing the phage.
• Designing hold points for in-process testing to confirm clearance before committing to expensive GMP-scale runs.

Process Development Considerations for an Endotoxin CDMO

Early Integration of Endotoxin Strategy

Building endotoxin removal into the process from day one avoids costly redesigns later. Host strain selection, amplification conditions, and lysis methods all impact endotoxin load.

Host Engineering

For some projects, using genetically modified Gram-negative hosts with reduced LPS content can dramatically lower initial endotoxin levels, simplifying downstream purification.

Scale-Up Effects

At larger scales, endotoxin behavior can change—aggregation, OMV formation, and clearance kinetics often shift with increased culture volumes and flow rates. A qualified Endotoxin CDMO anticipates these shifts through scale-down models and predictive process modeling.

---

Regulatory and Quality System Alignment

For a CDMO, meeting endotoxin specs is not just a technical challenge—it’s a compliance imperative. Regulators expect:

• Comprehensive batch records documenting endotoxin control points.
• Validated cleaning procedures for equipment to prevent cross-contamination.
• Training and competency assessments for staff handling endotoxin-sensitive operations.

Inconsistent endotoxin control can lead to batch rejections, inspection findings, and loss of client confidence—making it a top priority for any Endotoxin CDMO.

Conclusion: Why Endotoxin Expertise Defines a Phage CDMO’s Success

Endotoxin removal is not just a late-stage polishing step—it’s a critical capability that determines whether a phage therapy can meet the safety, potency, and regulatory expectations required for clinical and commercial use. An Endotoxin CDMO must weave this control into every stage of production, from upstream host strain design to downstream purification and final formulation, ensuring that clearance is achieved without compromising therapeutic activity.

The skill set is inherently cross-disciplinary: deep understanding of phage biology, the chemical behavior of endotoxins, process engineering for scalable purification, and the statistical rigor needed for process validation. A best-in-class Endotoxin CDMO balances purity with yield, avoiding over-processing that could weaken or destabilize the product, while still consistently meeting ultra-low endotoxin limits.

Mastery of endotoxin control also demonstrates regulatory readiness. It signals a mature quality system, proactive risk management, and the capability to adapt to evolving global guidelines. For sponsors, this makes the difference between a manufacturing vendor and a long-term strategic partner. In the emerging phage therapy market, those CDMOs who can reliably solve the endotoxin challenge will be positioned as leaders—driving faster approvals, safer products, and ultimately, wider adoption of phage-based solutions against drug-resistant infections.

Want to learn more about what it takes to be a top Phage CDMO? Read our other blog post on phages here—> What it takes to be a top-notch Phage CDMO.